NCT01952756View on ClinicalTrials.gov

Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Peripheral Arterial Diseases
Interventions
DRUG

Cilostazol

One tablet (100 mg) twice per day for 12 weeks

DRUG

Dummy Placebo

One tablet twice per day for 12 weeks

Trial Locations (1)

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

Department of Health, Executive Yuan, R.O.C. (Taiwan)

OTHER_GOV

lead

National Cheng-Kung University Hospital

OTHER

NCT01952756 - Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD) | Biotech Hunter | Biotech Hunter